Recommendations will help organizations that appraise new drugs establish whether their use will result in longer-term benefits for patients
Four health technology assessment agencies, including Canada’s Drug Agency, have published new guidance on the use of surrogate endpoints in cost-…
Canada’s Drug Agency is seeking to expand the group of scientists who contribute their expertise to our organization and help us power evidence-informed health technology decisions.
Within our organization, there is a need for timely access to skills that can supplement our existing capacity and…
Consultation status: Open Consultation period: January 6 to February 6, 2025
Canada’s Drug Agency is outlining additional plans to modernize the drug reimbursement review process and is seeking feedback on our proposed approaches.
The consultation document, Proposed Improvements to the Drug…
Canada's Drug Agency (CDA-AMC) and the Canadian Institute for Health Information (CIHI) have signed a 3-year agreement that will leverage the strengths of both organizations to build a stronger drug data and analytics foundation across Canada. This work will aim to advance CIHI’s Pharmaceutical…
Canada’s Drug Agency has received a letter from The Honourable Mark Holland that outlines our time-limited work related to An Act respecting pharmacare, which received royal assent on October 10, 2024.
We have begun to undertake the work outlined in the legislation and the letter, building on our…
Canada’s Drug Agency is proud to welcome Maureen Smith as the first-ever Patient Member on our Board of Directors. Maureen is a respected leader in the field of patient engagement, and she brings a unique perspective to our table, grounded in lived and living experience.
For the past 25…
A new coalition, announced today, unites 11 organizations that are working collectively to improve the appropriate prescribing and use of medications in Canada.
Initially formed in 2023, the Appropriate Use Coalition is a grassroots group comprised of health care organizations and public…
Current consultation status: Open Consultation period: November 28 to January 28, 2025
Canada’s Drug Agency is launching a consultation on our first-ever methods guide. The development of the guide and our open consultation are both part of our ambition to increase the transparency of our…
Canada’s Drug Agency, with support from our health system partners including ICES and Health Data Research Network Canada (HDRN), has published a new roadmap that will help those who manage patient and disease registries in Canada navigate the process of linking data records to help answer relevant…
Canada’s Drug Agency is pleased to announce the successful applicants from our 2024 Request for Proposals (RFP) to support the enhancement of rare disease registries in Canada. The awarded rare disease registries span diverse disease areas and will undertake varied improvement initiatives, all with…
Drug sponsors can now request a flexible service through our Scientific Advice program that can include a shorter time frame.
For Scientific Advice after pivotal trials designs are finalized, the program now offers more timely advice on anticipated key uncertainties or evidence gaps based on the…
Canada’s Drug Agency has released new guidance around aging in place. This guidance is intended to help health systems address Canada’s demographic transition toward an increasingly diverse aging population with an increased need for care and support during the later stages of life.
As health…